Fosamax-Related Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This established framework provides a baseline for recognizing how pharmaceutical interventions interact with physiological processes over time. Transitioning from this general health perspective, a more focused examination emerges regarding the biological plausibility of adverse outcomes associated with prolonged bisphosphonate exposure. Specifically, the relationship between Fosamax use and the development of osteonecrosis of the jaw represents a shift from population-level health education to a targeted risk assessment.

Bridge to Occupational Exposure Concerns

This concern becomes particularly salient in occupational settings where individuals may experience cumulative exposure through manufacturing, handling, or administration of the drug. The bridge concept here moves from a passive consumer health awareness to an active occupational exposure concern. In mass production environments, workers may face distinct patterns of contact with Fosamax compounds, raising questions about dose frequency, duration, and route of exposure that differ from typical patient scenarios. This pivot reframes the discussion from general therapeutic context to a workplace-specific hazard evaluation, without delving into mechanistic claims about disease causation.

Mechanistic Pathways of Fosamax-Induced ONJ

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The biological plausibility of a causal link between Fosamax and ONJ is supported by mechanistic pathways, clinical presentation, and documented adverse event reports. The primary mechanistic pathway involves bisphosphonate-induced suppression of bone turnover. Bisphosphonates, including alendronate, inhibit osteoclast-mediated bone resorption, which is their intended therapeutic effect for conditions like osteoporosis. However, in the jawbone, this suppression can become excessive, leading to impaired bone remodeling and repair. The jawbone has a high rate of turnover due to constant mechanical stress from chewing and the presence of teeth, making it particularly vulnerable to the effects of bisphosphonates. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This research indicates that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These changes can predispose the jawbone to necrosis, especially when combined with local trauma or infection.

Clinical Presentation and Risk Factors

Clinical presentation of ONJ includes exposed bone in the oral cavity that persists for more than eight weeks, often accompanied by pain, swelling, and infection. The condition is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was low and not statistically different from placebo, indicating that other factors, such as underlying risk factors, may contribute to its development.

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the label for Fosamax Plus D includes a more detailed list of risk factors and recommends that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians with information to assess risk and manage patients accordingly. Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The biological plausibility is supported by the known effects of bisphosphonates on bone turnover and the specific vulnerability of the jawbone. However, the low incidence in clinical trials and the association with other risk factors, such as dental procedures and comorbidities, complicate the establishment of direct causation in individual cases. For patients who develop ONJ while on Fosamax, the label advises discontinuation of the drug if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge with bisphosphonates further supports a causal relationship in susceptible individuals (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the biological plausibility of Fosamax-related ONJ is grounded in the drug's mechanism of action, which suppresses bone turnover, and the unique characteristics of the jawbone that make it susceptible to necrosis. Clinical evidence from adverse event reports and labeling information confirms the association, though the risk is influenced by duration of use, dental procedures, and other patient-specific factors. The prescribing information provides adequate warnings and guidance for risk mitigation, including consideration of drug discontinuation before invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility of Fosamax causing osteonecrosis of the jaw?

The biological plausibility is supported by Fosamax's mechanism of action: it suppresses bone turnover by inhibiting osteoclast activity. The jawbone has a high turnover rate due to mechanical stress, making it vulnerable. Research shows bisphosphonates alter jawbone mechanical stability and mineral density, predisposing to necrosis, especially with local trauma or infection (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, or infection. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.